Terms: = Endocrine gland cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL
5465 results:
1. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma.
Tang H; Miao X; Yu C; Chai C; Su Y; Li L; Yi J; Ye Z; Miao L; Wang Z; Zhang H; Xu H; Zhou W
Sci Rep; 2024 Apr; 14(1):9259. PubMed ID: 38649719
[TBL] [Abstract] [Full Text] [Related]
2. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
Çoban HŞ; Çil N; Önder E; Abban Mete G
Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
[TBL] [Abstract] [Full Text] [Related]
3. Multiple pathological fractures and muscle atrophy caused by a parathyroid carcinoma with postoperative hungry bone syndrome: A case report.
Liu Q; Zhang Y; Ma D; Gengzhi H; Maimaiti Y; Chen Q; Ma Z
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2047. PubMed ID: 38577726
[TBL] [Abstract] [Full Text] [Related]
4. A Survival Analysis of Patients with Recurrent Epithelial Ovarian cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia.
Harutyunyan L; Manvelyan E; Karapetyan N; Bardakhchyan S; Jilavyan A; Tamamyan G; Avagyan A; Safaryan L; Zohrabyan D; Movsisyan N; Avinyan A; Galoyan A; Sargsyan M; Harutyunyan M; Nersoyan H; Stepanyan A; Galstyan A; Danielyan S; Muradyan A; Jilavyan G
Curr Oncol; 2024 Mar; 31(3):1323-1334. PubMed ID: 38534933
[TBL] [Abstract] [Full Text] [Related]
5. Harmaline induces apoptosis and inhibits migration in A2780 ovarian cancer cells in vitro.
Shariat Razavi SA; Taghdisi Khaboushan M; Jafari R; Shahini A; Ferns GA; Bahrami A
Physiol Rep; 2024 Mar; 12(6):e15984. PubMed ID: 38531560
[TBL] [Abstract] [Full Text] [Related]
6. CRISPR du-HITI an attractive approach to targeting Long Noncoding RNA HCP5 as inhibitory factor for proliferation of ovarian cancer cell.
Moradi Z; Kazemi M; Jamshidi-Khalifelou R; Bahramnia V; Esfandmaz F; Rahnavard R; Moradgholi B; Piri-Gharaghie T
Funct Integr Genomics; 2024 Mar; 24(2):61. PubMed ID: 38507114
[TBL] [Abstract] [Full Text] [Related]
7. Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma.
Linder A; Westbom-Fremer S; Mateoiu C; Olsson Widjaja A; Österlund T; Veerla S; Ståhlberg A; Ulfenborg B; Hedenfalk I; Sundfeldt K
Hum Reprod; 2024 May; 39(5):1141-1154. PubMed ID: 38459814
[TBL] [Abstract] [Full Text] [Related]
8. HER2-low and Overexpression in Mucinous Ovarian cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
[TBL] [Abstract] [Full Text] [Related]
9. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
[TBL] [Abstract] [Full Text] [Related]
10. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T; Nguyen A; Misleh J; Cline VJ; Johns M; Shumway N; Paulson S; Siegel R; Larson T; Messersmith W; Richards D; Chaves J; Pierce E; Zalupski M; Sahai V; Orr D; Ruste SA; Haun A; Kawabe T
Eur J Cancer; 2024 Apr; 201():113950. PubMed ID: 38422585
[TBL] [Abstract] [Full Text] [Related]
11. Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.
Feharsal Y; Andrijono A; Singoprawiro CS; Lisnawati L; Pakasi TA; Putra AD; Kusuma F; Anggraeni TD; Erlina E; Sarwanti S; Mardhiyah T
Asian Pac J Cancer Prev; 2024 Feb; 25(2):513-519. PubMed ID: 38415537
[TBL] [Abstract] [Full Text] [Related]
12. Irreversible Electroporation-Induced Inflammation Facilitates Neutrophil-Mediated Drug Delivery to Enhance Pancreatic cancer Therapy.
Huang T; Wen X; Liang Y; Liu X; Zhao J; Long X
Mol Pharm; 2024 Apr; 21(4):1998-2011. PubMed ID: 38412284
[TBL] [Abstract] [Full Text] [Related]
13. Differences in Serum miRNA Profiles by Race, Ethnicity, and Socioeconomic Status: Implications for Developing an Equitable Ovarian cancer Screening Test.
Alimena S; Stephenson BJK; Webber JW; Wollborn L; Sussman CB; Packard DG; Williams M; Comrie CE; Wang JY; Markert T; Spiegel J; Rodriguez CB; Lightfoot M; Graye A; O'Connor S; Elias KM
Cancer Prev Res (Phila); 2024 Apr; 17(4):177-185. PubMed ID: 38388186
[TBL] [Abstract] [Full Text] [Related]
14. Clinical impacts of positive intraepithelial neoplasia at pancreatic transection margin in pancreatic cancer surgery.
Takada S; Makino I; Katano K; Sugita H; Tokoro T; Gabata R; Okazaki M; Nakanuma S; Ikeda H; Toyama T; Yagi S
Pancreatology; 2024 May; 24(3):493-496. PubMed ID: 38378436
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.
Qiu X; Lu C; Sha H; Zhu Y; Kong W; Tong F; Wang Q; Meng F; Liu B; Du J
Front Immunol; 2024; 15():1210859. PubMed ID: 38361920
[TBL] [Abstract] [Full Text] [Related]
16. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract] [Full Text] [Related]
17. Acetogenins from the Stem of
Gurgul A; Khin M; Souliya O; Sydara K; Burdette JE; Johnson JJ; Che CT
J Nat Prod; 2024 Feb; 87(2):207-216. PubMed ID: 38237151
[TBL] [Abstract] [Full Text] [Related]
18. The relationship between DNA mismatch repair gene and other prognostic parameters in pancreatic adenocarcinoma.
Urganci N; Kepil N; Ergun S; Bakkaloglu OK
J Surg Oncol; 2024 Apr; 129(5):876-884. PubMed ID: 38173349
[TBL] [Abstract] [Full Text] [Related]
19. Diagnostic Performance of [
Ventura D; Dittmann M; Büther F; Schäfers M; Rahbar K; Hescheler D; Claesener M; Schindler P; Riemann B; Seifert R; Roll W
J Nucl Med; 2024 Feb; 65(2):192-198. PubMed ID: 38164565
[TBL] [Abstract] [Full Text] [Related]
20. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic cancer.
Murthy P; Zenati MS; AlMasri SS; DeSilva A; Singhi AD; Paniccia A; Lee KK; Simmons RL; Bahary N; Lotze MT; Zureikat AH
J Natl Compr Canc Netw; 2023 Dec; 22(1D):e237070. PubMed ID: 38150819
[TBL] [Abstract] [Full Text] [Related]
[Next]
